Mar. 2021

## API PRODUCT PORTFOLIO

| PRODUCT | INDICATION | API MICRONIZED | CEP/DMF |
|---|---|---|---|
| **Arformoterol tartrate[P] polymorph A and D** | COPD | √ | US-CN DMF |
| **Formoterol fumarate** | Asthma and COPD | √ | CEP / US-JP-KR-CN DMF |
| **Glycopyrronium bromide[P]** | COPD | √ | CEP / US-CN DMF |
| **Indacaterol maleate[P]** | Asthma and COPD | √ | EU/US DMF |
| **Salmeterol xinafoate[P]** | Asthma and COPD | √ | CEP / US-CN-KR DMF |
| **Tiotropium bromide** | COPD | √ | CEP / US-CN DMF |
| **Vilanterol trifenatate** | Asthma and COPD | √ | EU DMF |

## API PRODUCT PIPELINE

| PRODUCT | INDICATION | SAMPLES | TECHNICAL PACKAGE | VALIDATION BATCH | DMF |
|---|---|---|---|---|---|
| **Abediterol** | Asthma and COPD | | | 2023 | 2023 |
| **Aclidinium bromide** | COPD | √ | √ | √ | Q3 2021 |
| **Batefenterol** | COPD | | | 2023 | 2024 |
| **Olodaterol[P]** | COPD | √ | √ | √ | Q2 2022 |
| **Revefenacin** | COPD | | | Q2 2021 | Q4 2021 |
| **Umeclidinium bromide** | COPD | √ | √ | Q2 2021 | Q4 2021 |

**CEP = Products with Certificate of Suitability / P = Patent applications/granted patents owned by Neuraxpharm**

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorization. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorization. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.